English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dupuytren’s disease (DD) is a common disease which leads to significant functional impairment of the hand. The recent introduction of Collagenase Clostridium Histolyticum (CCH) as a therapeutic option has changed the approach to disease management. Currently no management paradigm exists for treating Dupuytren’s disease within Australia. Methods: Databases were searched for Dupuytren’s disease patients receiving CCH. PRISMA guidelines were used to screen predefined classification of effectiveness, safety and recurrence of CCH. Results: In this review, 18 studies were included and analysed to evaluate the effectiveness, safety and recurrence of CCH. Conclusion: CCH has the potential as a non-surgical therapeutic option to expand the management paradigm for DD. This may minimise treatment time, cost and improve the public health care sector’s treatment of DD.

Dupuytren’s disease and collagenase: evidence for a paradigm shift in management